Incidence of primary hepatitis C infection among people who inject drugs during 2012–2020 in Athens, Greece
Journal of Viral Hepatitis · 2024
DOI: 10.1111/jvh.13951 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Sotirios Roussos und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Hepatitis C, Substance Abuse, Intravenous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie, MSD, Gilead Sciences.
Abstract (Originalsprache)
One of the World Health Organization's targets for the 2030 viral hepatitis elimination strategy is to reduce new hepatitis C (HCV) infections. In Athens, Greece, people who inject drugs (PWID) have a high HCV prevalence, with increasing trends since the 2000s. This analysis aims to assess primary HCV incidence among PWID during 2012–2020. Two community‐based interventions were implemented in 2012–2013 and 2018–2020 with repeated sero‐behavioural surveys in each period. Participants enrolled in multiple surveys were identified through linkage. To assess trends in HCV transmission, three indicators were estimated: (i) anti‐HCV prevalence among ‘new’ injectors (those injecting ≤2 years), (ii) indirect HCV incidence among ‘new’ injectors, assuming infection occurred at the midpoint between initiating injection and the first positive test, and (iii) HCV incidence from repeat participants. There were 431 and 125 ‘new’ injectors, respectively, in 2012–2013 and 2018–2020. Αnti‐HCV prevalence [95% CI] declined from 53.6% [48.8%, 58.3%] in 2012–2013 to 40.0% [31.3, 49.1%] in 2018–2020 (25.4% reduction, p = .007). The indirect estimate [95% CI] of HCV incidence among ‘new’ injectors decreased from 56.1 [49.3, 63.8] to 39.0/100 person‐years (PYs) [29.6, 51.5] (30.5% reduction, p = .020). HCV incidence [95% CI] based on seroconversions in repeat participants (16/63 in 2012–2013 and 9/55 in 2018–2020) declined from 64.6 [39.6105.4] to 13.8/100 PYs [7.2, 26.5], respectively (78.6% reduction, p < .001). Primary HCV incidence remains high among PWID in Athens. Consistent implementation of combined interventions, including high‐coverage harm reduction programs and initiatives tailored to increase access to HCV treatment, is essential to sustain the declining trends documented during 2012–2020.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Sotiria General Hospital, Athens, Greece.
- Gastroenterology Department, General Hospital of Athens Korgialeneio - Mpenakeio Hellenic Red Cross, Athens, Greece.
- Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases, Athens, Greece.
- First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Internal Medicine, General Hospital of Athens "Elpis", Athens, Greece.
ORCID-Profile: Sotirios Roussos, Evangelos Cholongitas, Peter Vickerman, Georgios Papatheodoridis, Vana Sypsa
Förderung
- AbbVie
- MSD
- Gilead Sciences
- Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases
- NSRF 2007-2013 (Operational Programme "Human Resources Development" 2007-2013, Priority Axis 14- Attika, Central Macedonia, Western Macedonia) and was cofunded…
- Meso Scale Diagnostics
Zitieren
APA
Roussos, S., Bagos, C., Angelopoulos, T., Chaikalis, S., Cholongitas, E., Savvanis, S., Papadopoulos, N., Kapatais, A., Chounta, A., Ioannidou, P., Deutsch, M., Manolakopoulos, S., Sevastianos, V., Papageorgiou, M. V., Vlachogiannakos, I., Mela, M., Elefsiniotis, I., Vrakas, S., Karagiannakis, D., …, & Sypsa, V. (2024). Incidence of primary hepatitis C infection among people who inject drugs during 2012–2020 in Athens, Greece. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13951
Vancouver
Roussos S, Bagos C, Angelopoulos T, Chaikalis S, Cholongitas E, Savvanis S, et al. Incidence of primary hepatitis C infection among people who inject drugs during 2012–2020 in Athens, Greece. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13951
BibTeX
@article{Roussos2024,
author = {Roussos, Sotirios and Bagos, Christos and Angelopoulos, Theodoros and Chaikalis, Savvas and Cholongitas, Evangelos and Savvanis, Spyridon and Papadopoulos, Nikolaos and Kapatais, Andreas and Chounta, Athina and Ioannidou, Panagiota and Deutsch, Melani and Manolakopoulos, Spilios and Sevastianos, Vasileios and Papageorgiou, Maria-Vasiliki and Vlachogiannakos, Ioannis and Mela, Maria and Elefsiniotis, Ioannis and Vrakas, Spyridon and Karagiannakis, Dimitrios and Pliarchopoulou, Fani and Psichogiou, Mina and Paraskevis, Dimitrios and Vickerman, Peter and Malliori, Meni and Kalamitsis, Georgios and Papatheodoridis, Georgios and Hatzakis, Angelos and Sypsa, Vana},
title = {Incidence of primary hepatitis C infection among people who inject drugs during 2012–2020 in Athens, Greece},
journal = {Journal of Viral Hepatitis},
year = {2024},
doi = {10.1111/jvh.13951}
}
EUVIMED